Daily Plenary Sessions
The daily plenary sessions feature some of the world’s most distinguished HIV scientists, policy specialists and community leaders. Plenary sessions bring all conference delegates together at the first session of every morning.
Plenary speakers will speak within a theme for each day (presentation titles are subject to change).
MONDAY 21 JULY: Where are we now?
Salim S. Abdool Karim, MD, PhD, South Africa
State of the art epidemiology & access
Salim S. Abdool Karim is an infectious diseases epidemiologist and clinician whose research contributions to HIV prevention and treatment are widely recognized. He is Director of the Centre for the AIDS Program of Research in South Africa (CAPRISA) and Pro Vice-Chancellor (Research) at the University of KwaZulu-Natal. He is also Professor of Clinical Epidemiology at Columbia University and Adjunct Professor of Medicine at Cornell University. Dr. Abdool Karim was co-leader of the CAPRISA 004 tenofovir gel trial that provided proof-of-concept that antiretroviral drugs prevent sexually transmitted HIV infection and herpes simplex virus type 2 in women. His clinical research on TB-HIV treatment has shaped international guidelines on the clinical management of co-infected patients. Dr Abdool Karim is Chair of the UNAIDS Scientific Expert Panel and serves on the PEPfAR Scientific Advisory Board, the Gates Foundation’s Global Health Scientific Advisory Board, the UNAIDS-Lancet Commission as well as the WHO Expert Panel on sexually transmitted infections and HIV.
Lydia Mungherera, MD, Uganda
PLHIV at the centre of the HIV response
Lydia Mungherera is a medical doctor, living positively with HIV. She is a treatment, gender and human rights activist for HIV positive women and is passionate about PLHIV and women’s sexual and reproductive health rights. Dr. Mungherera is the founder and co-founder of several organizations providing support to women in general and positive women in particular including the Athena Network, the Pan-African Coalition of Women Living with HIV and the Mama’s Club Uganda. The latter organization addresses the specific psychosocial needs and reproductive health rights of rural mothers living with HIV and was a recipient of the Red Ribbon Award at the International AIDS Conference in Mexico in 2008. More recently, she has been working on projects to improve the quality of women lives by mobilizing their partners, notably as a member of the Africa and Global Men Engage steering committees and by convening the Uganda Men Engage Network and Men Engage Consortium. At the international level, she has been contributing to the HIV counselling, prevention and treatment guidelines with UNAIDS and WHO as a civil society representative since 2003; she most recently reviewed the 2013 ARV treatment guidelines. In Uganda, she is a member of the National Maternal Child Health Cluster and PMTCT National Advisory Committee developing the Uganda PMTCT scale up plan and more recently, the National Task Force of the Option B+ implementation. Dr. Mungherera is a member of the Ugandan Health Policy Advisory Committee.
Jintanat Ananworanich, MD, PhD, Thailand
State of the ART: HIV Cure – where are we now and where are we going?
Jintanat Ananworanich is a paediatrician, immunologist and HIV researcher. For the past 13 years, she has led studies at the Thai Red Cross AIDS Research Center in Bangkok on HIV treatment in children and adults including acute HIV and HIV cure. From January 2014, she will continue her work on HIV cure in her new role as the Associate Director of HIV Therapeutic Trials at the US Military HIV Research Program in Maryland, United States. Dr. Ananworanich has authored more than 170 peer-reviewed publications on HIV. She is US board certified in Pediatrics, Allergy and Immunology, and in Clinical and Laboratory Immunology, and received her PhD in Medicine from the University of Amsterdam.
TUESDAY 22 JULY: What’s holding us back and how do we move faster?
Olive Shisana, MA, ScD, South Africa
Strengthening health systems and community
Olive Shisana is Chief Executive Officer of the Human Sciences Research Council (HSRC) in Pretoria, South Africa and is an Honorary Professor at the University of Cape Town. She was recently appointed to head South Africa’s BRICS Think Tank and to be the South African Co-Chair of the 2016 International AIDS Conference. In October 2013, Professor Shisana won the South African Academy of Sciences “Science-for-Society Gold Medal” for her work on HIV surveillance. She was a principal investigator for several second generation HIV surveillance systems and was one of the founders of the South African National Health and Nutrition Examination Survey as well as Maternal and Child Mortality Surveillance. She served on many national and international scientific committees and advisory boards, including the Ministerial Advisory Committee on National Health Insurance, the US Institute of Medicine’s Committee on Methodological Challenges in HIV Prevention Trials, and the South African National AIDS Council. Dr. Shisana holds a Doctor of Science from Johns Hopkins University and a Doctor of Laws honoris causa from Monash University for her lifelong contribution as a public health professional.
Jennifer Gatsi-Mallet, Namibia
Gender inequality and HIV
Jennifer Gatsi-Mallet is Director and founding member of the Namibia Women’s Health Network and the Namibia Country Officer for the International Community of Women Living with HIV. She has been living openly with HIV for the past 24 years, and has worked on HIV and AIDS issues since 2003. Ms Gatsi-Mallet is a leader in the fight for the rights of HIV-positive women around the world. She was recently involved in several projects aimed at bringing concrete changes to the lives of women in Namibia and Africa. Notably, since 2008 she has campaigned for the rights of HIV positive women subject to forced sterilization. The campaign has resulted in official court hearing of the cases and in 2012 the High Court of Namibia acknowledged that the three women in the case had effectively been subjected to coerced sterilization in violation of the laws of Namibia. In November 2013, the African Commission on Human and Peoples’ Rights condemned the practice of coerced sterilization of marginalized women, including women living with HIV. Ms. Gatsi-Mallet has contributed to research on sexual and reproductive health, HIV-positive women and women affected by HIV and has facilitated a number of workshops on issues ranging from gender based violence, sexual and reproductive health rights, treatment literacy to GIPA. She was the co-chair of the Community Programme Committee for the AIDS 2010 Conference in Vienna.
Mark Dybul, MD, The Global Fund to Fight AIDS, Tuberculosis and Malaria
Better and smarter investments in the HIV response
Mark Dybul is the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. He has worked on HIV and public health for more than 25 years as a clinician, scientist, teacher and administrator. After graduating from Georgetown Medical School in Washington D.C., he joined the National Institute of Allergy and Infectious Diseases, where he conducted basic and clinical studies on HIV virology, immunology and treatment optimization, including the first randomized, controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul became a founding architect and driving force in the formation of the President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical Officer, Assistant, Deputy and Acting director, in 2006 he was appointed as its leader, becoming U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Before coming to the Global Fund, he was co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law at Georgetown University, where he was also a Distinguished Scholar. Dr. Dybul has written extensively in scientific and policy literature, and has received several Honorary Degrees and awards.
WEDNESDAY 23 JULY: No one left behind
Khuat T. Oanh, MD, Vietnam
No one left behind: effective drug policy and harm reduction
Khuat Thi Hai Oanh is a medical doctor and the Founder and Executive Director of the Centre for Supporting Community Development Initiatives (SCDI), a Vietnamese non-government organisation whose mission is to improve the life of vulnerable populations through community empowerment and the creation of an enabling environment. SCDI serves sex workers, drug users, people living with HIV, their spouses and children as well as men who have sex with men and transgender people. Dr. Oanh has advocated for harm reduction and other effective, right-based treatment of drug users in Vietnam since 2003. During this time, Vietnam has legalized harm reduction programmes and moved from mandatory rehabilitation to more voluntary treatment of drug users. Dr. Oanh is the Chair of Vietnam Civil Society Partnership Platform on AIDS and Chair of Council of Representatives of the Asia Pacific Coalition of AIDS Service Organizations. In 2009, the World Economic Forum designated her as a Young Global Leader in recognition of her professional accomplishments and her contribution to important global issues.
Diane Havlir, MD, United States
No one left behind: HIV and tuberculosis co-infection
Diane Havlir is Professor of Medicine at the University of California, San Francisco and Chief of HIV at San Francisco General Hospital. She has worked as a clinician and researcher in HIV and tuberculosis, for 25 years conducting high impact research shaping treatment guidelines. Dr. Havlir played an active role on the global stage as an author of the first WHO Global HIV Treatment Guidelines and helped establish a Global HIV Drug Resistance surveillance programme. She served on the Board of the STOP TB partnership and chaired the WHO HIV and TB Working Group. She was elected to the Governing Council for the International AIDS Society and is an advisor to the Infectious Disease Center for Global Health Policy. Dr. Havlir was United States Co-chair of the International AIDS Conference in Washington DC in 2012, and an architect of the DC Declaration, a nine point plan to end AIDS.
Daisy Nakato Namakula, Uganda
No one left behind: HIV and sex workers
Daisy Nakato Namakula is a sex worker, a sex worker activist and an advocate for sex workers rights in Uganda. As an activist she has come out and spoken strongly against abuse and violence against sex-workers in Uganda, and won a case against the Uganda Government Attorney General regarding police harassment – having personally suffered police brutality while conducting outreach services among sex workers at night. Ms. Nakato is a founding member and the current Executive Director of the Women’s Organization Network for Human Rights Advocacy (WONETHA), a sex worker-led organization in Uganda, working to mobilize sex workers and form cohesive groups in which they can address HIV and AIDS. Through her work, she highlights sex workers issues and strategies in local, national and global forums, including conferences, workshops, interviews, peaceful demonstrations and sex workers coalitions and networks. She has been involved in measures to reduce media mis-information about sex-workers by speaking openly about sex worker issues and sharing her story as a sex worker living with HIV.
James Ward, BA, Australia
No one left behind: HIV and indigenous populations
James Ward is the Deputy Director and the Head of Preventive Health at Baker IDI in Alice Springs, Central Australia. He is a descendent of the Pitjantajarra and Nurrunga clans of central and south Australia and has over twenty years’ experience in Aboriginal health, public health, policy development and implementation, epidemiology, research, and research ethics. He is a specialist in sexually-transmitted infections (STIs) and HIV/AIDS in Australian Aboriginal communities and a member of the Federal Ministerial Advisory Committee on blood borne viruses and STIs. He is a leader on the International Indigenous Working Group on HIV/AIDS, and a lead investigator on more than ten research studies aiming to address and control STIs and HIV among Indigenous Australians. He has a strong interest in building capabilities in communities to enable self-determination. James is nearing the completion of his PhD in the domains of epidemiology, STIs and HIV and Australian Aboriginal and Torres Strait Islander communities.
THURSDAY 24 JULY: Stepping up the pace: making the long term short term
Antonio Lanzavecchia, MD, Switzerland
Stepping up the pace on an HIV vaccine: what needs to be done?
Antonio Lanzavecchia is the Founding Director of the Institute for Research in Biomedicine in Bellinzona. Prior to this appointment in 1999, he was a member of the Basel Institute for Immunology. Dr. Lanzavecchia is also professor of Human Immunology at the ETH Zurich. He was awarded the warded with the EMBO medal in 1988 and the Cloëtta prize in 1999. He has published more than 250 papers and his research covers several aspects of human immunology: from antigen processing and presentation to dendritic cell biology, from lymphocyte activation and traffic to immunological memory and human monoclonal antibodies. Antonio Lanzavecchia holds a degree in Medicine from the University of Pavia where he specialized in Pediatrics and in Infectious Diseases.
Kenneth Mayer, MD, United States
Stepping up the pace on new prevention technologies
Kenneth Mayer is the Medical Research Director of Fenway Health and Co-Chair of the Fenway Institute in Boston, United States. He is also Professor of Medicine at Harvard Medical School, Professor in the Department of Global Health and Population at the Harvard School of Public Health, and Attending Physician at the Beth Israel Deaconess Medical Center. Dr. Mayer is an Infectious Disease physician, who diagnosed some of the first Bostonians living with AIDS when he began working at Fenway Health in the early 1980s. He studied the natural history and transmission of HIV, helping to lead bio-behavioral HIV prevention studies, including some of the first anti-HIV vaccine and topical and oral chemoprophylaxis trials. He has co-authored more than 500 scientific publications, and co-edited 5 academic texts. He is a member of the Governing Council of the International AIDS Society and has served on the national boards of the American Foundation for AIDS Research (amfAR), the HIV Medicine Association (HIVMA) and the Gay and Lesbian Medical Association (GLMA).
Beatriz Grinsztejn, MD, PhD, Brazil
Stepping up the pace for MSM and transgender – understanding the science
Beatriz Grinsztejn is the Director of the STD/AIDS Clinical Research Laboratory at the Clinical Research Institute Evandro Chagas (IPEC/FIOCRUZ) and the Principal Investigator of its HIV Prevention and Therapeutic Clinical Trials Unit. The unit is involved in community-based HIV Prevention and Therapeutic clinical trials and cohort studies in Rio de Janeiro, Brazil. Dr. Grinsztejn also serves as an Infectious Disease Physician and Researcher at the Oswaldo Cruz Foundation. She is technical advisor for the Brazilian Advisory Committee for Antiretroviral Therapy in adults and serves as a member of both the WHO 2013 Adult Antiretroviral Therapy Guidelines Panel and the UNAIDS Scientific Expert Panel. Dr. Grinsztejn has devoted her career to the study and management of HIV/AIDS; she currently leads several projects in Brazil to expand and enhance research on biomedical prevention for men who have sex with men and transgender women, and specifically, the use of antiretrovirals for prevention, and diagnosis and management of acute HIV infection.
Laurindo Garcia, Philippines
Stepping up the pace for MSM and transgender – the community response
Laurindo Garcia is a civil society and social justice advocate based between the Philippines and Singapore. As the coordinator for two regional community networks promoting health for sexual and gender minorities and a person living openly with HIV he is often called to give a perspective of people living with or affected by HIV in the Asia-Pacific region. Laurindo founded an international social enterprise group called B-Change that seeks to promote social change through technology. The B-Change Group is set to launch a portfolio of multilingual web-apps designed to crowd-source peer support in early 2014: firstly an app for gay men and other men who have sex with men living with HIV (PLUS), and the other for young people from sexual and gender minorities (BE). Laurindo is a global ambassador of the ‘Here I Am’ Campaign - an international campaign calling on world leaders to save millions of lives by supporting a fully funded Global Fund to Fight AIDS, Tuberculosis and Malaria.
FRIDAY 25 JULY: Where are we headed?
David Cooper, MD, DSc (UNSW), Australia
Where are we headed with ART – beyond an undetectable viral load
Professor David Cooper AO is a Professor of Medicine at the University of New South Wales and a Fellow of the Australian Academy of Science (FAA). Professor Cooper is also Director of the Kirby Institute for infection and immunity in society based in Sydney, Australia. The Kirby Institute is funded by the Australian Government Department of Health and Ageing, to conduct research into the HIV/AIDS epidemic in Australia, with the ultimate aim of reducing the burden of the HIV/AIDS epidemic for the affected community. Professor Cooper is a consultant physician to the HIV Immunology Service at St Vincent’s Hospital, Sydney and is a Director of HIV-NAT, a clinical research and trials collaboration based at the Thai Red Cross AIDS Research Centre at the Chulalongkorn University Hospital in Bangkok, Thailand. He is a past President of the International AIDS Society (IAS).
Susan Kasedde, MPH, DrPH, UNICEF
Where are we headed with HIV and adolescents
Susan Kasedde currently serves as Senior Advisor and Team Leader on HIV and Adolescents for UNICEF. Since 2009 she has contributed towards global level evidence generation, technical guidance development, advocacy, and global partnership development towards a stronger global response on HIV prevention, treatment and care in adolescents aged 10 – 19, a group previously largely neglected. Dr. Kasedde has coordinated a series of studies including documentation of global practices in the care of adolescents living with HIV, mathematical modeling with the Futures Institute to assess the impact and cost of scale up of proven HIV prevention, treatment and care interventions on new HIV infections and AIDS deaths in adolescents, and a systematic review with the London School of Hygiene and Tropical Medicine to confirm evidence on effective programmatic approaches to reduce HIV infection, illness and death in adolescents. This work contributed to stronger advocacy and guidelines, including the new 2013 WHO guidelines on HIV testing, counseling and care in adolescents. Dr. Kasedde has 18 years of experience working on adolescents’ sexual and reproductive health of which 16 focused on HIV. Dr. Kasedde holds a doctorate in Epidemiology and Population Health from the London School of Hygiene and Tropical Medicine and a Master’s degree in Public Health from Boston University.
L'Orangelis Thomas Negron, Puerto Rico
Where are we headed with HIV and adolescents
L'Orangelis Thomas Negron is a young free-spirited woman, strengthened by HIV. She is working every day in HIV prevention, and with young people and women so that people living with HIV have a better quality of life and can live free of stigma. L’Orangelis is 25 years old; she was born HIV-positive in San Juan, Puerto Rico where she still lives. On 1 December 2008, L’Orangelis publicly shared her HIV status; the following year she became a certified HIV counsellor and worked for two years as a youth peer facilitator. In 2011 she began blogging her experiences as a young woman born with HIV and in 2012 she became part of a collaborative group of feminists who write an online page entitled Ovaries of Steel
discussing challenges facing women living with HIV. L’Orangelis is part of the Latin-American and Caribbean Positive Youth Network.
Shaffiq Essajee, MD, United States
Where are we headed on ending AIDS in children
Shaffiq Essajee is the Senior Medical Advisor for the Clinton Health Access Initiative and a member of the Pediatric Infectious Disease Faculty at New York University where he has been caring for children with HIV for the past 18 years. He hails from Kenya and in 2001 he established one of the first free pediatric HIV clinics in the region in the city of Mombasa. He recently spent two years In Geneva working for the World Health Organization as the Medical Officer for Pediatric and Family Care. In addition to his work as a clinician and public health advocate, Dr. Essajee is also a research scientist and has been supported by the NIH Center for AIDS Research and the Doris Duke Charitable Foundation. He is a graduate of the Oxford University Medical School, and completed his residency in pediatrics at the University of California, San Francisco before joining the Pediatric Infectious Disease Division at New York University.